Medicaments for slowing parkinson's disease

Abstract

Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease.

1 .- 6 . (canceled) 
     
     
         7 . A method of slowing or delaying progression of Parkinson's Disease, wherein the method comprises administering to a patient diagnosed with for Parkinson's Disease an effective amount
 opicapone without levodopa;   
       wherein, the method prevents or postpones late motor complications or fluctuations. 
     
     
         8 .- 9 . (canceled) 
     
     
         10 . The method of  claim 7 , wherein the slowing of the progression of Parkinson's Disease involves a delay in the progression of Parkinson's Disease by a period of at least one month. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 7 , wherein opicapone is administered once a day. 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 7 , wherein the dose of opicapone is 25 mg to 100 mg. 
     
     
         15 .- 20 . (canceled) 
     
     
         21 . The method of  claim 7 , wherein the method reduces the periods in which the patient exhibits Parkinson's disease symptoms by more than 0.25 hr per day. 
     
     
         22 .- 41 . (canceled) 
     
     
         42 . The method of  claim 7 , wherein the patient has not previously taken a dopamine agonist, a dopamine precursor, a catechol-o-methyl transferase (COMT) inhibitor, a monoamine oxidase-B (MAO-B) inhibitor, or an anti-cholinergic. 
     
     
         43 . The method of claim  41 , wherein the patient has not previously taken a dopamine precursor, wherein the dopamine precursor is levodopa. 
     
     
         44 . A medicament comprises opicapone with levodopa for slowing or delaying progression of Parkinson's Disease.